ClinicalTrials.gg
CompletedNCT00501618Updated Apr 15, 2015

Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder

A Phase 4 interventional study of Fazaclo in Schizophrenia and Schizoaffective Disorder, sponsored by Manhattan Psychiatric Center. Completed at 2 sites in United States. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2015-04-15.

Sponsored by Manhattan Psychiatric Center · Phase 4, Interventional, and Basic science

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
All
01

Study summary

The purpose of this study is to obtain data on equivalence of generic clozapine to Fazaclo (orally disintegrating tablet). Generic clozapine is the most frequently used clozapine and such data is important for clinicians to have.

Read the detailed description

The primary objective of this study is to determine the equivalence of generic clozapine tablets to FazaClo in patients with schizophrenia or schizoaffective disorder who are already taking generic clozapine and are switched to FazaClo.

In this study, patients receiving a stable twice-daily dose of generic clozapine formulation for the past one month will be switched to FazaClo. A trough steady-state clozapine and desmethylclozapine concentrations will be taken thrice while patient is on generic Clozapine. After the third clozapine level patients will be switched from their generic clozapine formulation to FazaClo, at the same dosage and treatment regimen as the generic clozapine formulation they had been receiving. Trough steady-state clozapine and desmethylclozapine concentration levels will be taken twice, 7 days and 14 days after starting Fazaclo.

02

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Schizophrenia
  • Schizoaffective Disorder
  • Orally dissolving clozapine
  • orally disintegrating clozapine
  • bio-equivalence
  • desmethylclozapine
  • clozapine plasma level
  • equivalence
  • fazaclo
  • generic clozapine
03

In context

Schizophrenia

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's enrollment of 20 is below the median of 71 across 2,944 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Manhattan Psychiatric Center is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients (male or female) are between 18 and 59 years of age.
  • Female patients are not pregnant or breastfeeding and those who are not surgically sterilized, (at least six months), or sexually abstinent are using adequate methods (defined as diaphragm, condom, foam/jellies, sponge, and/or oral contraceptives).
  • Patients have a diagnosis of 1) treatment-resistant schizophrenia or; 2) schizophrenia, chronic (all types) and in a residual phase or in remission, or schizoaffective disorder according to , Fourth Edition (DSM-IV) criteria and are judged to be at chronic risk for reexperiencing suicidal behavior based on history and recent clinical state. In addition, all patients must have a total score on the PANSS of 90 or less.
  • Patients have been on a generic clozapine formulation for one month prior to Visit 1 with no changes in clozapine or psychotropic medication dosage in the past one month. Clozapine dose is administered twice daily.
  • Patients have no abnormalities in the medical history, physical examination, and clinical laboratory tests.
  • Patients have given written consent after being advised of the nature and risks of the study and are competent to sign an Form.
  • Patients who have shown inconsistent clozapine plasma levels or inconsistent clinical response with a therapeutically adequate daily dose of clozapine as documented in the medical chart or documented by nursing notes about patients' cheeking the oral tablets of clozapine for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Patients are included in the National Non-Rechallenge Master File for Clozaril.
  • Patients have a medical or surgical condition that might interfere with the absorption, metabolism, or excretion of clozapine or FazaClo.
  • Patients have a history of granulocytopenia or myeloproliferative disorder, either drug-induced or idiopathic.
  • Patients have a total white blood cell (WBC) count below 4000/mm3 or an (ANC) below 2000/mm3.
  • Patients have a history of cardiovascular, renal, hepatic, respiratory, endocrine (except noninsulin-dependent diabetes mellitus), or gastrointestinal disease.
  • Patients have a known history of infection.
  • Patients have a history of epilepsy or seizures or are comatose or experiencing severe central nervous system depression.
  • Patients are unable to communicate with the investigator.
  • Patients have a history of allergic reactions to clozapine or chemically related psychotropic drugs.
  • Patients have a concurrent primary psychiatric or neurological diagnosis, including organic mental disorder ( criteria), mental retardation, severe tardive dyskinesia, or idiopathic Parkinson's disease.
  • Patients have had electroconvulsive therapy within the past three months.
  • Patients have demonstrated clinically significant homicidal behavior within the past 12 months.
  • Patients have received an drug within the past 30 days.
  • Patients have a history of narrow-angle glaucoma.
  • Patients require treatment with drugs that are known to interact with clozapine (e.g., agents having a well-known potential to suppress bone-marrow functioning, drugs that are highly protein-bound, cimetidine, or phenytoin). Clozapine may also potentiate the effects of antihypertensives and anticholinergics; therefore, caution should be taken if patients receiving these drugs are enrolled in the study.
  • Patients are morbidly obese (defined as having a [BMI] greater than 40; BMI = weight [kg]/height [m2]).
  • Patients have a known history of phenylketonuria. FazaClo contains aspartame, a source of phenylalanine which can be harmful to patients with phenylketonuria.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Other
    Fazaclo

    open label switch from generic clozapine to Fazaclo

    Drug: Fazaclo

Interventions

  • single-arm

    Also known as: Fazaclo clozapine

06

What researchers measure

Primary outcomes

  1. To determine the equivalence of generic clozapine tablets to FazaClo in patients with schizophrenia or schizoaffective disorder who are already taking generic clozapine and are switched to FazaClo.

    Time frame: 14 days

Secondary outcomes

  1. Whether side effects are comparable when equivalent plasma levels are present

    Time frame: 14 days

  2. Whether clinical efficacy is maintained after the switch to Fazaclo

    Time frame: 14 days

07

Study locations

2 sites
  • Manhattan Psychiatric Center, 125th Street, Out Patient Clinic
    New York, New York 10027, United States
  • Manhattan Psychiatric Center, Inpatient Unit
    New York, New York 10035, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00501618
Lead sponsor
Manhattan Psychiatric Center
Collaborators
Azur Pharma, Inc
Responsible party
Jean-Pierre Lindenmayer (Clinical Director, Manhattan Psychiatric Center) — Principal investigator
First posted
Jul 16, 2007
Start date
Nov 2006
Primary completion
Mar 2009
Completion
Jul 2009
Last update
Apr 15, 2015

Study contacts

Jean-Pierre Lindenmayer, MD
principal investigator · Manhattan Psychiatric Center
Saurabh Kaushik, MD
study chair · Nathan Kline Institute & Manhattan Psychiatric Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clozapine

Start the discussion